Book a demo
Winner · Create Apps ChampionshipDubai’s App of the Year 2026and Longevity App of the Year

Health, made visibleDubai, UAE

The most expensive pill is the one we never took.

Kwelio makes health routines visible, starting with the medicines people take at home, so insurers, doctors and care teams can help before it is too late.

01Meet Sara

SaraAn illustrative member, not a real patient

Sara takes her medicines at home, out of sight.

Sara has diabetes and takes medication every day. Like many people with a long-term condition, she sometimes misses a dose, or takes it late. No one sees it.

  • 50%of people with chronic conditions don’t take their medicines as prescribed WHO, 2003
  • 20.7%of UAE adults live with diabetes on an age-adjusted basis, among the highest prevalence rates in the world IDF, 2024

02What no one sees

Her insurer sees what was dispensed, not whether it was taken.

By the time a missed dose shows up anywhere, it is usually a hospital visit.

  • 3.4Mpeople in the UAE may not be taking their medicines as prescribed Kwelio estimate
  • $5–7Ba year: the estimated cost of non-adherence in the UAE Kwelio estimate

The UAE in numbers

How we worked this out.

  1. 11.3 millionpeople lived in the UAE in 2024: 11,294,243 residents, according to the Federal Competitiveness and Statistics Centre. Source
  2. × 60% = 6.8 millionliving with at least one long-term condition. This share is Kwelio’s working assumption in its market model, not a published national figure.
  3. × 50% = 3.4 millionwho may not be taking their medicines as prescribed. The WHO: “in developed countries, adherence among patients suffering from chronic diseases averages only 50%, and it is even lower in developing countries.” Source
  4. $5–7 billion a yearthe estimated cost of non-adherence in the UAE: preventable hospital stays, avoidable complications and claims. Estimated from UAE healthcare expenditure data (FCSC, 2024) and global benchmarks for the cost of medication that is not working as intended (Watanabe et al., Annals of Pharmacotherapy, 2018). A range, not a measured figure. Benchmark study

For context: in the Ministry of Health and Prevention’s National Health and Nutrition Survey 2024–2025, 25.9% of UAE adults have high blood pressure and 54.2% have high cholesterol. Reported by Gulf News, January 2026

03What we believe

“The best technology is technology that you don’t have to think about.”

So Kwelio fits into the moment Sara already has, and keeps everything else out of sight: for her, for her care team, and for her doctor.

Kwelio in one minute.

One photo at each dose. Assisted verification: Kwelio suggests what it can see, and she confirms against her schedule.

One score from 0 to 100. How consistently someone keeps to their medicines, over 30 days.

Who to reach first. Kwelix gives a care team a short list. The care team decides.

Calm technology. No streak that resets, no leaderboards, nothing to lose.

Pick where Kwelio lives. Atmospheric design: six terrains, four times of day. Try one, and move the sun.

The care team sees the score. Not the photos, not the daily logs.

04 · POP by Kwelio

A few seconds at each dose.

One reminder on her schedule. One photo of her medicines: Kwelio suggests what it can see, and she confirms what she took against her schedule. A record she owns. We call it the Pop ritual.

Assisted verification: photo capture with confirmation against her schedule. Our computer-vision model is in training. A photo and a dose log are a record, not proof that a medicine was taken.

A screen recording of the evening Pop: Sara photographs her medicines, Kwelio suggests the ones it can see, she confirms what she took and six doses are logged with a photo
Sample data

05 · Sara and her care team

Her phone. Their screen.

What Sara does in a few seconds becomes something her care team can act on, without her day being watched.

The Today screen of POP by Kwelio
Sara’s KAS in POP by Kwelio, with what would help most
Refills in POP by Kwelio: what Sara is running low on
Sara’s report in POP by Kwelio, ready to share with her doctor or pharmacist
Worth knowing in POP by Kwelio: things to mention to a pharmacist or doctor, each with its source
Privacy and policies in POP by Kwelio

One calm moment at each dose.

Sara sees what to take and when. At each dose time she takes one photo, Kwelio suggests what it can see, and she confirms. Her day stays hers.

Kwelix shows demonstration data

06 · The score

One number a care team can act on.

KAS, the Kwelio Adherence Score, shows how consistently a member keeps to their medicines. KIS, the Kwelio Intervention Score, flags who might need support soon.

  • 0–100KAS, over a rolling 30 days. No score until a member has 14 days and 10 scheduled doses.
  • 0.88AUROC on CMS DE-SynPUF (US Medicare synthetic claims), 2.1M de-duplicated records. It shows the method works, not that it is proven on a UAE cohort.
  • NeverDuring pilots, the score is never used for cover or premiums.

The score

KAS, the Kwelio Adherence Score.

How consistently a member keeps to their medicines, from 0 to 100 over a rolling 30 days: completion weighted by how critical each medicine is, photo-assisted logging, timing, and runs of missed doses.

No score until a member has 14 days and 10 scheduled doses; until then the member is calibrating, never zero. The weights are expert-set and will be refitted on the first real cohort.

The priority

KIS, the Kwelio Intervention Score.

The likelihood of a lapse and how much it would matter, so outreach starts with the members it would help most. The care team sets the alert threshold within published ranges.

The model behind it: AUROC 0.88 on CMS DE-SynPUF (US Medicare synthetic claims), 2.1M de-duplicated records. It shows the method works, not that it is proven on a UAE cohort.

Insurers pay for outcomes they never see coming.

For more than two decades I sat on the payer side.

We funded every hospitalization, and we saw almost none of them coming.

Mohamad AtayaCCO

07 · Their screen

What her care team sees.

Kwelix gives an insurer’s care team a short list of who to reach first, and why, with each member’s score and what is behind it. Kwelio prioritises. Your care team decides.

Demonstration data

The outreach queue is ranked by KIS, and Sara is first with a KIS of 72 because her dose times are slipping and a refill is four days late. Her KAS is 75, down 9 points in 30 days: taken 85%, with a photo 70%, on time 50%, no long gaps 83%. Her care team sees her medication score and whether she might need support, not her photos or daily logs.

640enrolled58calibrating12to reach today

Outreach queue ranked by KIS

  1. 72KISSaraKAS 75 −9 in 30 daysDose times slippingRefill 4 days late
  2. 63KISMember CKAS 71 −5 in 30 daysTwo missed evening doses
  3. 48KISMember AKAS 79 −2 in 30 daysNew medicine added
  4. 41KISMember DKAS 83 +1 in 30 daysSide effects reported
  5. 36KISMember EKAS 86 0 in 30 daysCalm week

Sara

Age band 45–54 · E11 type 2 diabetes · I10 high blood pressure · 3 medicines

Might need support

KAS last 30 days

75−9

KIS who to reach first

72

  • Likelihood of a lapse
  • What a lapse would cost

Why her KAS is 75

  • Takenweighted by criticality85%
  • With a photoassisted verification70%
  • On timewithin an hour50%
  • No long gapslongest missed run83%
Log outreachSnooze 14 days
640enrolled58calibrating582with a score

The cohort last 30 days

  • 74median KAS
  • 12might need support today
  • +5average KAS over 12 weeks

Members still calibrating, without 14 days and 10 scheduled doses, are left out, and any cohort under 5 members is hidden.

Members by KAS range 582 with a score

KAS from 0 to 100, in steps of 10. The lighter bars are under 50.

Programme report September 2026

A monthly summary for the programme team, in cohort figures only.

46outreach logged9snoozed21newly scored73average KAS
Download PDFExport CSV

Average KAS by week, 12 weeks

A report carries cohort figures only: never photos or daily logs, and never an individual’s reasons without their consent to outreach.

A sample screen with demonstration data. During pilots, the score is never used for cover or premiums. Kwelix

08 · A proven idea

Measuring what people do changed lending and car insurance. Medication is next.

When a market can see what people actually do, it stops guessing. Kwelio brings that shift to the medicines people take at home.

  1. Lending · 1989

    The credit score

    The FICO score turned a payment history into one number. Lenders use it to decide who qualifies, and on what terms. American Express

  2. Car insurance · late 1990s

    Telematics

    A small device plugged into the car, and now a phone app, records how people actually drive: miles, time of day, hard braking. Insurers can price for the risk each driver really carries, so careful drivers benefit. NAIC

  3. Medication · now

    KAS, the Kwelio Adherence Score

    The doses a person logs become one consistent measure, from 0 to 100 over 30 days. Their care team can see who might need support, and members earn Lio Points for keeping to their schedule. During pilots, the score is never used for cover or premiums.

Healthcare is already moving this way. In the UK, an NHS study is testing connected inhaler sensors that record each dose and share it with a child’s medical team. NIHR Leicester BRC, 2024

09 · The bigger picture

Making health routines visible, so the people who can help, can.

Kwelio turns what people do every day for their health, starting with their medicines, into scores and records that insurers, doctors and care providers can act on. The infrastructure stays out of sight, so people can get on with their lives.

An ecosystem, not an app

Everyone with a stake in someone staying well.

Kwelio starts with health insurers. The others are where we are heading, each with the member’s consent.

  • Health insurers

    Reach the right member early, before a missed dose becomes a claim.

  • Life insurers and takaful

    In health insurance, a healthy member saves a claim. In life insurance, a healthy member is the whole business.

  • Doctors and pharmacists

    Decisions about a treatment that start from what actually happened at home.

  • Clinic networks and labs

    Patients who keep to their treatment, show up and come back.

  • Employers and fitness chains

    Health and benefits programmes that people take part in.

  • Families and older people

    A dispenser that hands out each dose on time, and family who can follow along when the member chooses to share.

Prevention

Help that arrives before the hospital does.

In developed countries, adherence to long-term therapy for chronic illness averages around 50% (WHO, 2003).

Non-adherence is associated with up to 10% of US hospital admissions, and accounts for 33–69% of medication-related hospitalisations.

When a care team can see a lapse beginning, it can reach the person while a phone call is still enough.

Longevity

Staying well for longer is a routine, not an event.

Most of what keeps a person well happens on ordinary days: the medicine taken on time, the habit kept. Kwelio starts with medicines because they are the routine that matters most for people with long-term conditions.

The same record, shared with the member’s consent, matters to everyone with a stake in someone living well for longer: their family, their doctor, their insurer.

Doctors and care teams

Better decisions start from what happened.

A prescription records what was intended. Kwelio records what happened at home, so a doctor reviewing a treatment, a test or a change starts from the real picture.

Kwelio shows; the professional decides. Interaction notices are worded from prescribing information and framed as something to raise with a pharmacist or doctor, never an instruction to change a medicine.

Health insurers

From what was dispensed to what was taken.

In a US study of over 857,000 chronic patients, adherence was associated with annual medical cost savings of roughly $4,400–$5,300 per patient with comorbidities.

Kwelix gives an insurer’s care team a short list of who to reach first. During pilots, the score is never used for cover or premiums.

Built in Dubai

Where the need is close to home.

20.7% of UAE adults live with diabetes on an age-adjusted basis, among the highest prevalence rates in the world (IDF, 2024).

Non-communicable disease cost the UAE an estimated AED 39.9 billion in 2019, of which around AED 26 billion was cardiovascular disease.

10 · Why we started

Two stories. One root problem.

When my grandmother fell dangerously ill, we discovered she had been given the wrong medication and another dose had been doubled. There was no system to catch it.

Mohamed AlrahmaCo-founder and CEO

I was quoted AED 80,000 a year for health insurance because I have a chronic condition, priced for the risk of not taking my medication. That’s the exact problem Kwelio solves.

Sumi MahmudCo-founder and CTO

11 · What’s next

: every dose, in order.

Kwelio’s own dispenser, designed from scratch. Today’s LioBox is manual and comes with Beads by Kwelio. The next one dispenses each dose on schedule and syncs with POP by Kwelio, so older people can keep to their medicines without fussing with an app.

In development withDubai Health Innovations

Recognition

Recognised by the people who know.

All news
  • Dubai’s App of the Year 2026 presented to Kwelio on stage, beside the Kwelio logo
    Photo: Dubai Chamber of Digital Economy
    Create Apps in Dubai, an initiative by Dubai Chamber Digital

    Award · October 2026

    Dubai’s App of the Year 2026 and Longevity App of the Year 2026

    POP by Kwelio won both at the Create Apps Championship, part of the #CreateAppsInDubai initiative by Dubai Chamber Digital.

    The pitch, the moment and the press

  • London Business School

    Competition · 2026

    Top 10 finalist, LBS MENA Startup Competition 2026

    London Business School. Final Demo Day in Dubai on 14 October 2026.

  • NEXUS

    Accelerator · 2026

    Accepted into NEXUS

    The Khalifa Fund accelerator.

  • Annual Health Awards 2025

    Award · 2025

    Best Health & Wellness Startup of the Year 2025

    Annual Health Awards.

  • MIT DesignX

    Accelerator

    MIT DesignX

    Selected for MIT DesignX.

  • Global Recognition Awards

    Award · 2025

    Global Recognition Award 2025

    Wellness Innovator, in the Science, Technology & Social Design category.

  • F6S

    Ranking · May 2026

    #7 HealthTech company on F6S, May 2026

    F6S

  • Dubai Health Innovations

    Collaboration

    In collaboration with Dubai Health Innovations

    On the next LioBox and Adherence Packaging.

From the Journal

Medicines, supplements and health, explained.

All articles

For health insurers

Ready to make adherence visible?

Book a 30-minute demo. We’ll walk you through Kwelix, the KAS and KIS scores, and how a pilot works.